Focused On-demand Library for High affinity immunoglobulin epsilon receptor subunit alpha

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P12319

UPID:

FCERA_HUMAN

Alternative names:

Fc-epsilon RI-alpha; IgE Fc receptor subunit alpha

Alternative UPACC:

P12319

Background:

The High affinity immunoglobulin epsilon receptor subunit alpha, also known as Fc-epsilon RI-alpha or IgE Fc receptor subunit alpha, plays a pivotal role in immune response. It acts as a high-affinity receptor for IgE, mediating effector functions in myeloid cells. This receptor's activation on mast cells, basophils, and eosinophils leads to the release of inflammatory mediators, contributing to tissue remodeling, cytotoxicity against microbes, and immediate hypersensitivity to allergens.

Therapeutic significance:

Understanding the role of High affinity immunoglobulin epsilon receptor subunit alpha could open doors to potential therapeutic strategies. Its central role in allergic reactions and immune defense mechanisms against pathogens highlights its potential as a target for treating allergic conditions and enhancing immune responses.